Effects of Acthar on Recovery From Cognitive Relapses in MS
Study Details
Study Description
Brief Summary
The purpose of this study is to evaluate the effect of a medication called Acthar on recovery from multiple sclerosis-related relapses that impact cognition.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 3 |
Detailed Description
This is a prospective, open-label study of Acthar administered as treatment for an acute cognitive relapse. Primary and secondary endpoints will be collected prior to Acthar administration and at 3-month follow-up. Comparison will be made to a stable MS control group.
The objectives of the study are:
-
To replicate prior findings with steroid therapy for MS patients for cognitive relapses, using instead Acthar Gel as the treating agent. The investigators will determine if the decrease on cognitive endpoints at the time of relapse exceeds that of stable MS controls.
-
To compare the effects above to a previously acquired dataset of relapsing patients treated with steroids. This is a quasi-experimental design in so far as the steroid treated group data were previously acquired in a separate study.
The primary hypothesis of the study is that, due to the enhanced melanocortin response in Acthar the recovery from cognitive changes occurring during cognitively focused relapse will be significant compared to stable MS patients matched on age, time since testing, and cognitive performance on the SDMT.
Target enrollment for the Acthar treatment group will be 30 MS patients under care at the Jacobs Neurological Institute with existing neuropsychological baseline in the past four years in whom a cognitive relapse or new supratentorial GAD enhancing lesion(s) on MRI have been identified. Cognitive relapse will be identified based on clinical presentation of acute worsening of cognitive symptoms in the domains of processing speed, concentration, episodic memory, working memory, and/or fatigue. Patients whose clinical MRI indicate new active GAD enhancing lesions will be screened for the presence of self-perceived cognitive decline, without new physical symptoms. Thirty (30) clinically stable MS patients matched on age, time since testing, and cognitive performance on the SDMT will be recruited from the pool of patients with existing cognitive baselines.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Cognitively Relapsing Patients For individuals experiencing cognitive relapses/exacerbations, 5ml/80 IU of Adrenocorticotropic Hormone will be administered through either subcutaneous or intramuscular self-injection (selected by the patient) for 5-days. |
Drug: Adrenocorticotropic Hormone
Acthar Gel will be administered in accordance with the recommendations set forth in the package insert. The dosage may be individualized according to the medical condition of each patient. Frequency and dose of the drug may be determined by considering the severity of the disease and the initial response of the patient.
Other Names:
|
No Intervention: Stable Multiple Sclerosis Patients Individuals whose Multiple Sclerosis is currently in a stable state (not currently or recently exacerbating) are age-matched with relapsing MS patients. There is no intervention for individuals with MS whose are currently in a stable state. |
Outcome Measures
Primary Outcome Measures
- Change From Baseline on the Symbol Digit Modalities Test (SDMT) [Day 0 and Day 90]
A measure of visual processing speed and working memory. Minimum score of 0, Maximum score of 120. Higher scores indicate better performance. The difference in total correct responses on the SDMT from Day 0 to Day 90 were analyzed to address change in this outcome.
- Timed 25-foot Walk [Day 0 and Day 90]
An MS-specific measure of functional status walking speed. How many seconds does it take to walk 25 feet. Ceiling value of 300 seconds.
- Change From Baseline on the Paced Auditory Serial Addition Test (PASAT) [Day 0 and Day 90]
A measure of auditory processing speed and working memory. Minimum value of 0, maximum value of 60. Higher score indicates better performance. The difference in total correct on the PASAT from Day 0 to Day 90 were analyzed to address change in this outcome.
- Change From Baseline on the Brief Visuospatial Memory Test-Revised (BVMT-R) [Day 0 and Day 90]
A measure of visual/spatial memory. Minimum of 0, maximum of 36. Higher score indicates better performance. The difference in total learning score on the BVMT-R from Day 0 to Day 90 were analyzed to address change in this outcome.
- Change From Baseline on the California Verbal Learning Test, Second Edition (CVLT-II) [Day 0 and Day 90]
A measure of auditory/verbal episodic memory. Minimum of 0, maximum of 80. Higher score indicates better performance. The difference in total learning score on the CVLT-II from Day 0 to Day 90 were analyzed to address change in this outcome.
Secondary Outcome Measures
- Change From Baseline on the Expanded Disability Status Scale (EDSS). [Day 0 and Day 90]
A clinician assigned measure of disability specific to MS. Minimum of 0 (no disability), maximum of 10 (death due to MS). Higher scores indicate greater disability. The difference in total score on the EDSS from Day 0 to Day 90 were analyzed to address change in this outcome.
- Change From Baseline on the Multiple Sclerosis Neuropsychological Questionnaire (MSNQ) [Day 0 and Day 90]
A self and informant rating measure of perceived cognitive problems. Minimum of 0, maximum of 60. Higher scores indicates greater self-reported neuropsychological impairment. The difference in total score on the MSNQ from Day 0 to Day 90 were analyzed to address change in this outcome.
- Change From Baseline on the Beck Depression Inventory-Fast Screen (BDI-FS) [Day 0 and Day 90]
A self-report, multiple choice inventory of depression. Minimum of 0, maximum of 21. Higher score indicates higher levels of depression. The difference in total score on the BDI-FS from Day 0 to Day 90 were analyzed to address change in this outcome.
- Change From Baseline on the Fatigue Severity Scale (FSS) [Day 0 and Day 90]
A self-report measure of fatigue. 1 (no fatigue) to 9 (severe fatigue). The difference in total score on FSS from Day 0 to Day 90 were analyzed to address change in this outcome.
Other Outcome Measures
- Incidence of Adverse Events [Up to 3 months]
The number of patients reporting adverse events over the course of the study
- Change From Baseline in Concurrent Medications [Up to 3 months]
Initiation or discontinuation of any medications occurring over the course of the study; monitored by clinician and study personnel.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Males/Females between 18 and 65 years of age who are capable of understanding and complying with the protocol (ie. have completed at least a 9th grade education and are fluent English).
-
Have a diagnosis of Relapsing Remitting MS (RRMS) or early Secondary Progressive MS (SPMS) as per revised McDonald's Criteria.
-
Have an Expanded Disability Severity Scale (EDSS) of ≤ 7.0.
-
Have had valid neuropsychological testing (NP) within the past 4 years
-
Experiencing an acute cognitive relapse identified by a clinical care provider as a.) a cognitive symptom of recent origin developing over 48 hours, or b.) supratentorial GAD enhancing lesions on MRI with confirmed cognitive decline.
- Confirmation of cognitive decline will be obtained by administering the Symbol Digit Modalities Test (SDMT) as a screening procedure for the study and comparing it to scores obtained within 4 years (see inclusion criteria #4). Participants qualify if a raw point change on the SDMT greater than or equal to -3 points is detected.
-
Are capable of performing the requirements of neuropsychological (NP) testing, including near visual acuity 20/70 or better with correction.
-
Have given written informed consent prior to any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to his/her future medical care.
Exclusion Criteria:
-
Are found to have evidence on MRI of new lesions in the brainstem, spinal cord, or optic nerve.
-
Have clear new physical signs or symptoms that are referable to the cord, brainstem or optic nerve.
-
Have cognitive deficits/impairment caused by concomitant medication usage, or are attributable to another medical condition or significant neurological/psychological disease.
-
Have evidence of current major depression as determined by a positive Beck Depression Inventory-Fast Screen (BDI-FS) and clinician interview.
-
Patients with changes to medications known to influence cognition (narcotics, stimulants, etc.) or disease modifying therapy within one month of study initiation (or within a time frame deemed high risk by treating physician) will be excluded.
-
Are taking any medication, or have any medical condition contraindicated with Acthar.
-
Presence of current infections as determined by clinician interview.
-
Are currently nursing, intentionally seeking pregnancy, or deemed at-risk for unplanned pregnancy.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | University at Buffalo-State University of New York, Department of Neurology, Buffalo General Hospital | Buffalo | New York | United States | 14203 |
Sponsors and Collaborators
- State University of New York at Buffalo
Investigators
- Principal Investigator: Ralph HB Benedict, PhD, University of Buffalo-State University of New York
Study Documents (Full-Text)
More Information
Publications
- Amato MP, Ponziani G, Rossi F, Liedl CL, Stefanile C, Rossi L. Quality of life in multiple sclerosis: the impact of depression, fatigue and disability. Mult Scler. 2001 Oct;7(5):340-4.
- Amato MP, Ponziani G, Siracusa G, Sorbi S. Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years. Arch Neurol. 2001 Oct;58(10):1602-6.
- Benedict R. Brief Visuospatial Memory Test - Revised: Professional Manual. Odessa, Florida: Psychological Assessment Resources, 1997.
- Benedict RH, Bruce J, Dwyer MG, Weinstock-Guttman B, Tjoa C, Tavazzi E, Munschauer FE, Zivadinov R. Diffusion-weighted imaging predicts cognitive impairment in multiple sclerosis. Mult Scler. 2007 Jul;13(6):722-30. Epub 2007 Mar 15.
- Benedict RH, Cookfair D, Gavett R, Gunther M, Munschauer F, Garg N, Weinstock-Guttman B. Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc. 2006 Jul;12(4):549-58.
- Benedict RH, Fischer JS, Archibald CJ, Arnett PA, Beatty WW, Bobholz J, Chelune GJ, Fisk JD, Langdon DW, Caruso L, Foley F, LaRocca NG, Vowels L, Weinstein A, DeLuca J, Rao SM, Munschauer F. Minimal neuropsychological assessment of MS patients: a consensus approach. Clin Neuropsychol. 2002 Aug;16(3):381-97. Review.
- Benedict RH, Holtzer R, Motl RW, Foley FW, Kaur S, Hojnacki D, Weinstock-Guttman B. Upper and lower extremity motor function and cognitive impairment in multiple sclerosis. J Int Neuropsychol Soc. 2011 Jul;17(4):643-53.
- Benedict RH, Munschauer F, Linn R, Miller C, Murphy E, Foley F, Jacobs L. Screening for multiple sclerosis cognitive impairment using a self-administered 15-item questionnaire. Mult Scler. 2003 Feb;9(1):95-101.
- Benedict RH, Ramasamy D, Munschauer F, Weinstock-Guttman B, Zivadinov R. Memory impairment in multiple sclerosis: correlation with deep grey matter and mesial temporal atrophy. J Neurol Neurosurg Psychiatry. 2009 Feb;80(2):201-6. doi: 10.1136/jnnp.2008.148403. Epub 2008 Oct 1.
- Benedict RH, Zivadinov R. Predicting neuropsychological abnormalities in multiple sclerosis. J Neurol Sci. 2006 Jun 15;245(1-2):67-72. Epub 2006 Apr 19.
- Benedict RH, Zivadinov R. Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nat Rev Neurol. 2011 May 10;7(6):332-42. doi: 10.1038/nrneurol.2011.61. Review.
- Benedict RHB, Schretlen D, Groninger L, Dobraski M, Shpritz B. Revision of the Brief Visuospatial Memory Test: Studies of normal performance, reliability, and validity. Psychological Assessment 8:145-153, 1996.
- Feuillet L, Reuter F, Audoin B, Malikova I, Barrau K, Cherif AA, Pelletier J. Early cognitive impairment in patients with clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler. 2007 Jan;13(1):124-7.
- Filippini G, Brusaferri F, Sibley WA, Citterio A, Ciucci G, Midgard R, Candelise L. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev. 2000;(4):CD001331. Review.
- Fischer JS, Rudick RA, Cutter GR, Reingold SC. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler. 1999 Aug;5(4):244-50. Review.
- Foong J, Rozewicz L, Quaghebeur G, Thompson AJ, Miller DH, Ron MA. Neuropsychological deficits in multiple sclerosis after acute relapse. J Neurol Neurosurg Psychiatry. 1998 Apr;64(4):529-32.
- Frohman EM, Shah A, Eggenberger E, Metz L, Zivadinov R, Stüve O. Corticosteroids for multiple sclerosis: I. Application for treating exacerbations. Neurotherapeutics. 2007 Oct;4(4):618-26. Review.
- Gilson BS, Gilson JS, Bergner M, Bobbit RA, Kressel S, Pollard WE, Vesselago M. The sickness impact profile. Development of an outcome measure of health care. Am J Public Health. 1975 Dec;65(12):1304-10.
- Glanz BI, Holland CM, Gauthier SA, Amunwa EL, Liptak Z, Houtchens MK, Sperling RA, Khoury SJ, Guttmann CR, Weiner HL. Cognitive dysfunction in patients with clinically isolated syndromes or newly diagnosed multiple sclerosis. Mult Scler. 2007 Sep;13(8):1004-10. Epub 2007 Jul 10.
- Gronwall DM. Paced auditory serial-addition task: a measure of recovery from concussion. Percept Mot Skills. 1977 Apr;44(2):367-73.
- Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 Nov;33(11):1444-52.
- Morrow SA, Jurgensen S, Forrestal F, Munchauer FE, Benedict RH. Effects of acute relapses on neuropsychological status in multiple sclerosis patients. J Neurol. 2011 Sep;258(9):1603-8. doi: 10.1007/s00415-011-5975-3. Epub 2011 Mar 8. Erratum in: J Neurol. 2011 Sep;258(9):1609.
- Patti F, Pozzilli C, Montanari E, Pappalardo A, Piazza L, Levi A, Onesti E, Pesci I; Italian Study Group On Quality Of Life In Ms. Effects of education level and employment status on HRQoL in early relapsing-remitting multiple sclerosis. Mult Scler. 2007 Jul;13(6):783-91. Epub 2007 Feb 16.
- Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology. 1991 May;41(5):685-91.
- Shah A, Eggenberger E, Zivadinov R, Stüve O, Frohman EM. Corticosteroids for multiple sclerosis: II. Application for disease-modifying effects. Neurotherapeutics. 2007 Oct;4(4):627-32. Review.
- Simmons RD, Tribe KL, McDonald EA. Living with multiple sclerosis: longitudinal changes in employment and the importance of symptom management. J Neurol. 2010 Jun;257(6):926-36. doi: 10.1007/s00415-009-5441-7. Epub 2010 Jan 19.
- Smith A. Symbol digit modalities test: Manual. Los Angeles: Western Psychological Services, 1982.
- 465028
Study Results
Participant Flow
Recruitment Details | |
---|---|
Pre-assignment Detail |
Arm/Group Title | Cognitively Relapsing Patients | Stable Multiple Sclerosis Patients |
---|---|---|
Arm/Group Description | For individuals experiencing cognitive relapses/exacerbations, 5ml/80 IU of Adrenocorticotropic Hormone will be administered through either subcutaneous or intramuscular self-injection (selected by the patient) for 5-days. Adrenocorticotropic Hormone: Acthar Gel will be administered in accordance with the recommendations set forth in the package insert. The dosage may be individualized according to the medical condition of each patient. Frequency and dose of the drug may be determined by considering the severity of the disease and the initial response of the patient. | Individuals whose Multiple Sclerosis is currently in a stable state (not currently or recently exacerbating) are age-matched with relapsing MS patients. There is no intervention for individuals with MS whose are currently in a stable state. |
Period Title: Overall Study | ||
STARTED | 30 | 34 |
COMPLETED | 29 | 32 |
NOT COMPLETED | 1 | 2 |
Baseline Characteristics
Arm/Group Title | Cognitively Relapsing Patients | Stable Multiple Sclerosis Patients | Total |
---|---|---|---|
Arm/Group Description | For individuals experiencing cognitive relapses/exacerbations, 5ml/80 IU of Adrenocorticotropic Hormone will be administered through either subcutaneous or intramuscular self-injection (selected by the patient) for 5-days. Adrenocorticotropic Hormone: Acthar Gel will be administered in accordance with the recommendations set forth in the package insert. The dosage may be individualized according to the medical condition of each patient. Frequency and dose of the drug may be determined by considering the severity of the disease and the initial response of the patient. | Individuals whose Multiple Sclerosis is currently in a stable state (not currently or recently exacerbating) are age-matched with relapsing MS patients. There is no intervention for individuals with MS whose are currently in a stable state. | Total of all reporting groups |
Overall Participants | 25 | 25 | 50 |
Age (Count of Participants) | |||
<=18 years |
0
0%
|
0
0%
|
0
0%
|
Between 18 and 65 years |
25
100%
|
25
100%
|
50
100%
|
>=65 years |
0
0%
|
0
0%
|
0
0%
|
Age (years) [Mean (Standard Deviation) ] | |||
Mean (Standard Deviation) [years] |
42.4
(10.7)
|
43.8
(10.5)
|
43.1
(10.6)
|
Sex: Female, Male (Count of Participants) | |||
Female |
20
80%
|
22
88%
|
42
84%
|
Male |
5
20%
|
3
12%
|
8
16%
|
Race (NIH/OMB) (Count of Participants) | |||
American Indian or Alaska Native |
0
0%
|
0
0%
|
0
0%
|
Asian |
1
4%
|
0
0%
|
1
2%
|
Native Hawaiian or Other Pacific Islander |
0
0%
|
0
0%
|
0
0%
|
Black or African American |
2
8%
|
3
12%
|
5
10%
|
White |
22
88%
|
22
88%
|
44
88%
|
More than one race |
0
0%
|
0
0%
|
0
0%
|
Unknown or Not Reported |
0
0%
|
0
0%
|
0
0%
|
Symbol Digit Modalities Test (Total Correct) [Mean (Standard Deviation) ] | |||
Mean (Standard Deviation) [Total Correct] |
55.2
(13.5)
|
55.9
(12.4)
|
55.6
(13.0)
|
California Verbal Learning Test, 2nd Edition (Total Learning Score) [Mean (Standard Deviation) ] | |||
Mean (Standard Deviation) [Total Learning Score] |
51.4
(12.6)
|
49.1
(11.1)
|
50.3
(11.9)
|
Brief Visuospatial Memory Test Revised (BVMTR) (Total Learning Score) [Mean (Standard Deviation) ] | |||
Mean (Standard Deviation) [Total Learning Score] |
23.1
(7.1)
|
23.9
(7.0)
|
23.5
(7.1)
|
Timed 25-foot Walk (Seconds) [Mean (Standard Deviation) ] | |||
Mean (Standard Deviation) [Seconds] |
5.4
(1.9)
|
5.0
(1.2)
|
5.2
(1.6)
|
Multiple Sclerosis Neuropsychological Screening Questionnaire (MSNQ) (Total Score) [Mean (Standard Deviation) ] | |||
Mean (Standard Deviation) [Total Score] |
30.1
(12.6)
|
18.0
(8.9)
|
24.1
(10.8)
|
Expanded Disability Status Scale (EDSS) (Total Score) [Median (Inter-Quartile Range) ] | |||
Median (Inter-Quartile Range) [Total Score] |
2.5
|
2.5
|
2.5
|
Fatigue Severity Scale (FSS) (Total Score) [Mean (Standard Deviation) ] | |||
Mean (Standard Deviation) [Total Score] |
4.9
(1.6)
|
4.2
(1.5)
|
4.6
(1.6)
|
Outcome Measures
Title | Change From Baseline on the Symbol Digit Modalities Test (SDMT) |
---|---|
Description | A measure of visual processing speed and working memory. Minimum score of 0, Maximum score of 120. Higher scores indicate better performance. The difference in total correct responses on the SDMT from Day 0 to Day 90 were analyzed to address change in this outcome. |
Time Frame | Day 0 and Day 90 |
Outcome Measure Data
Analysis Population Description |
---|
The sample used for final analysis was smaller than the total enrolled (see Participant Flow) because participants were excluded from the final analysis due to (1) withdrawal prior to follow-up, (2) occasional missing data from one or more timepoints, and (3) to optimize matching of the groups based on demographic characteristics. |
Arm/Group Title | Cognitively Relapsing Patients | Stable Multiple Sclerosis Patients |
---|---|---|
Arm/Group Description | For individuals experiencing cognitive relapses/exacerbations, 5ml/80 IU of Adrenocorticotropic Hormone will be administered through either subcutaneous or intramuscular self-injection (selected by the patient) for 5-days. Adrenocorticotropic Hormone: Acthar Gel will be administered in accordance with the recommendations set forth in the package insert. The dosage may be individualized according to the medical condition of each patient. Frequency and dose of the drug may be determined by considering the severity of the disease and the initial response of the patient. | Individuals whose Multiple Sclerosis is currently in a stable state (not currently or recently exacerbating) are age-matched with relapsing MS patients. There is no intervention for individuals with MS whose are currently in a stable state. |
Measure Participants | 25 | 25 |
Mean (Standard Deviation) [Total Correct] |
44.6
(13.9)
|
58.5
(13.9)
|
Title | Timed 25-foot Walk |
---|---|
Description | An MS-specific measure of functional status walking speed. How many seconds does it take to walk 25 feet. Ceiling value of 300 seconds. |
Time Frame | Day 0 and Day 90 |
Outcome Measure Data
Analysis Population Description |
---|
The sample used for final analysis was smaller than the total enrolled (see Participant Flow) because participants were excluded from the final analysis due to (1) withdrawal prior to follow-up, (2) occasional missing data from one or more timepoints, and (3) to optimize matching of the groups based on demographic characteristics. |
Arm/Group Title | Cognitively Relapsing Patients | Stable Multiple Sclerosis Patients |
---|---|---|
Arm/Group Description | For individuals experiencing cognitive relapses/exacerbations, 5ml/80 IU of Adrenocorticotropic Hormone will be administered through either subcutaneous or intramuscular self-injection (selected by the patient) for 5-days. Adrenocorticotropic Hormone: Acthar Gel will be administered in accordance with the recommendations set forth in the package insert. The dosage may be individualized according to the medical condition of each patient. Frequency and dose of the drug may be determined by considering the severity of the disease and the initial response of the patient. | Individuals whose Multiple Sclerosis is currently in a stable state (not currently or recently exacerbating) are age-matched with relapsing MS patients. There is no intervention for individuals with MS whose are currently in a stable state. |
Measure Participants | 25 | 25 |
Mean (Standard Deviation) [Seconds] |
6.7
(3.2)
|
5.3
(1.2)
|
Title | Change From Baseline on the Paced Auditory Serial Addition Test (PASAT) |
---|---|
Description | A measure of auditory processing speed and working memory. Minimum value of 0, maximum value of 60. Higher score indicates better performance. The difference in total correct on the PASAT from Day 0 to Day 90 were analyzed to address change in this outcome. |
Time Frame | Day 0 and Day 90 |
Outcome Measure Data
Analysis Population Description |
---|
The sample used for final analysis was smaller than the total enrolled (see Participant Flow) because participants were excluded from the final analysis due to (1) withdrawal prior to follow-up, (2) occasional missing data from one or more timepoints, and (3) to optimize matching of the groups based on demographic characteristics. |
Arm/Group Title | Cognitively Relapsing Patients | Stable Multiple Sclerosis Patients |
---|---|---|
Arm/Group Description | For individuals experiencing cognitive relapses/exacerbations, 5ml/80 IU of Adrenocorticotropic Hormone will be administered through either subcutaneous or intramuscular self-injection (selected by the patient) for 5-days. Adrenocorticotropic Hormone: Acthar Gel will be administered in accordance with the recommendations set forth in the package insert. The dosage may be individualized according to the medical condition of each patient. Frequency and dose of the drug may be determined by considering the severity of the disease and the initial response of the patient. | Individuals whose Multiple Sclerosis is currently in a stable state (not currently or recently exacerbating) are age-matched with relapsing MS patients. There is no intervention for individuals with MS whose are currently in a stable state. |
Measure Participants | 25 | 25 |
Mean (Standard Deviation) [Total Correct] |
40.1
(12.2)
|
47.0
(14.3)
|
Title | Change From Baseline on the Brief Visuospatial Memory Test-Revised (BVMT-R) |
---|---|
Description | A measure of visual/spatial memory. Minimum of 0, maximum of 36. Higher score indicates better performance. The difference in total learning score on the BVMT-R from Day 0 to Day 90 were analyzed to address change in this outcome. |
Time Frame | Day 0 and Day 90 |
Outcome Measure Data
Analysis Population Description |
---|
The sample used for final analysis was smaller than the total enrolled (see Participant Flow) because participants were excluded from the final analysis due to (1) withdrawal prior to follow-up, (2) occasional missing data from one or more timepoints, and (3) to optimize matching of the groups based on demographic characteristics. |
Arm/Group Title | Cognitively Relapsing Patients | Stable Multiple Sclerosis Patients |
---|---|---|
Arm/Group Description | For individuals experiencing cognitive relapses/exacerbations, 5ml/80 IU of Adrenocorticotropic Hormone will be administered through either subcutaneous or intramuscular self-injection (selected by the patient) for 5-days. Adrenocorticotropic Hormone: Acthar Gel will be administered in accordance with the recommendations set forth in the package insert. The dosage may be individualized according to the medical condition of each patient. Frequency and dose of the drug may be determined by considering the severity of the disease and the initial response of the patient. | Individuals whose Multiple Sclerosis is currently in a stable state (not currently or recently exacerbating) are age-matched with relapsing MS patients. There is no intervention for individuals with MS whose are currently in a stable state. |
Measure Participants | 25 | 25 |
Mean (Standard Deviation) [Total Learning Score] |
22.0
(8.9)
|
22.5
(7.9)
|
Title | Change From Baseline on the California Verbal Learning Test, Second Edition (CVLT-II) |
---|---|
Description | A measure of auditory/verbal episodic memory. Minimum of 0, maximum of 80. Higher score indicates better performance. The difference in total learning score on the CVLT-II from Day 0 to Day 90 were analyzed to address change in this outcome. |
Time Frame | Day 0 and Day 90 |
Outcome Measure Data
Analysis Population Description |
---|
The sample used for final analysis was smaller than the total enrolled (see Participant Flow) because participants were excluded from the final analysis due to (1) withdrawal prior to follow-up, (2) occasional missing data from one or more timepoints, and (3) to optimize matching of the groups based on demographic characteristics. |
Arm/Group Title | Cognitively Relapsing Patients | Stable Multiple Sclerosis Patients |
---|---|---|
Arm/Group Description | For individuals experiencing cognitive relapses/exacerbations, 5ml/80 IU of Adrenocorticotropic Hormone will be administered through either subcutaneous or intramuscular self-injection (selected by the patient) for 5-days. Adrenocorticotropic Hormone: Acthar Gel will be administered in accordance with the recommendations set forth in the package insert. The dosage may be individualized according to the medical condition of each patient. Frequency and dose of the drug may be determined by considering the severity of the disease and the initial response of the patient. | Individuals whose Multiple Sclerosis is currently in a stable state (not currently or recently exacerbating) are age-matched with relapsing MS patients. There is no intervention for individuals with MS whose are currently in a stable state. |
Measure Participants | 25 | 25 |
Mean (Standard Deviation) [Total Learning Score] |
46.6
(14.1)
|
51.2
(11.8)
|
Title | Change From Baseline on the Expanded Disability Status Scale (EDSS). |
---|---|
Description | A clinician assigned measure of disability specific to MS. Minimum of 0 (no disability), maximum of 10 (death due to MS). Higher scores indicate greater disability. The difference in total score on the EDSS from Day 0 to Day 90 were analyzed to address change in this outcome. |
Time Frame | Day 0 and Day 90 |
Outcome Measure Data
Analysis Population Description |
---|
The sample used for final analysis was smaller than the total enrolled (see Participant Flow) because participants were excluded from the final analysis due to (1) withdrawal prior to follow-up, (2) occasional missing data from one or more timepoints, and (3) to optimize matching of the groups based on demographic characteristics. |
Arm/Group Title | Cognitively Relapsing Patients | Stable Multiple Sclerosis Patients |
---|---|---|
Arm/Group Description | For individuals experiencing cognitive relapses/exacerbations, 5ml/80 IU of Adrenocorticotropic Hormone will be administered through either subcutaneous or intramuscular self-injection (selected by the patient) for 5-days. Adrenocorticotropic Hormone: Acthar Gel will be administered in accordance with the recommendations set forth in the package insert. The dosage may be individualized according to the medical condition of each patient. Frequency and dose of the drug may be determined by considering the severity of the disease and the initial response of the patient. | Individuals whose Multiple Sclerosis is currently in a stable state (not currently or recently exacerbating) are age-matched with relapsing MS patients. There is no intervention for individuals with MS whose are currently in a stable state. |
Measure Participants | 25 | 25 |
Median (Inter-Quartile Range) [Total Score] |
3.0
|
2.0
|
Title | Change From Baseline on the Multiple Sclerosis Neuropsychological Questionnaire (MSNQ) |
---|---|
Description | A self and informant rating measure of perceived cognitive problems. Minimum of 0, maximum of 60. Higher scores indicates greater self-reported neuropsychological impairment. The difference in total score on the MSNQ from Day 0 to Day 90 were analyzed to address change in this outcome. |
Time Frame | Day 0 and Day 90 |
Outcome Measure Data
Analysis Population Description |
---|
The sample used for final analysis was smaller than the total enrolled (see Participant Flow) because participants were excluded from the final analysis due to (1) withdrawal prior to follow-up, (2) occasional missing data from one or more timepoints, and (3) to optimize matching of the groups based on demographic characteristics. |
Arm/Group Title | Cognitively Relapsing Patients | Stable Multiple Sclerosis Patients |
---|---|---|
Arm/Group Description | For individuals experiencing cognitive relapses/exacerbations, 5ml/80 IU of Adrenocorticotropic Hormone will be administered through either subcutaneous or intramuscular self-injection (selected by the patient) for 5-days. Adrenocorticotropic Hormone: Acthar Gel will be administered in accordance with the recommendations set forth in the package insert. The dosage may be individualized according to the medical condition of each patient. Frequency and dose of the drug may be determined by considering the severity of the disease and the initial response of the patient. | Individuals whose Multiple Sclerosis is currently in a stable state (not currently or recently exacerbating) are age-matched with relapsing MS patients. There is no intervention for individuals with MS whose are currently in a stable state. |
Measure Participants | 25 | 25 |
Mean (Standard Deviation) [Total Score] |
34.5
(9.4)
|
20.0
(12.3)
|
Title | Change From Baseline on the Beck Depression Inventory-Fast Screen (BDI-FS) |
---|---|
Description | A self-report, multiple choice inventory of depression. Minimum of 0, maximum of 21. Higher score indicates higher levels of depression. The difference in total score on the BDI-FS from Day 0 to Day 90 were analyzed to address change in this outcome. |
Time Frame | Day 0 and Day 90 |
Outcome Measure Data
Analysis Population Description |
---|
[Not Specified] |
Arm/Group Title | Cognitively Relapsing Patients | Stable Multiple Sclerosis Patients |
---|---|---|
Arm/Group Description | For individuals experiencing cognitive relapses/exacerbations, 5ml/80 IU of Adrenocorticotropic Hormone will be administered through either subcutaneous or intramuscular self-injection (selected by the patient) for 5-days. Adrenocorticotropic Hormone: Acthar Gel will be administered in accordance with the recommendations set forth in the package insert. The dosage may be individualized according to the medical condition of each patient. Frequency and dose of the drug may be determined by considering the severity of the disease and the initial response of the patient. | Individuals whose Multiple Sclerosis is currently in a stable state (not currently or recently exacerbating) are age-matched with relapsing MS patients. There is no intervention for individuals with MS whose are currently in a stable state. |
Measure Participants | 25 | 25 |
Mean (Standard Deviation) [Total Score] |
5.0
(4.0)
|
1.6
(2.8)
|
Title | Change From Baseline on the Fatigue Severity Scale (FSS) |
---|---|
Description | A self-report measure of fatigue. 1 (no fatigue) to 9 (severe fatigue). The difference in total score on FSS from Day 0 to Day 90 were analyzed to address change in this outcome. |
Time Frame | Day 0 and Day 90 |
Outcome Measure Data
Analysis Population Description |
---|
The sample used for final analysis was smaller than the total enrolled (see Participant Flow) because participants were excluded from the final analysis due to (1) withdrawal prior to follow-up, (2) occasional missing data from one or more timepoints, and (3) to optimize matching of the groups based on demographic characteristics. |
Arm/Group Title | Cognitively Relapsing Patients | Stable Multiple Sclerosis Patients |
---|---|---|
Arm/Group Description | For individuals experiencing cognitive relapses/exacerbations, 5ml/80 IU of Adrenocorticotropic Hormone will be administered through either subcutaneous or intramuscular self-injection (selected by the patient) for 5-days. Adrenocorticotropic Hormone: Acthar Gel will be administered in accordance with the recommendations set forth in the package insert. The dosage may be individualized according to the medical condition of each patient. Frequency and dose of the drug may be determined by considering the severity of the disease and the initial response of the patient. | Individuals whose Multiple Sclerosis is currently in a stable state (not currently or recently exacerbating) are age-matched with relapsing MS patients. There is no intervention for individuals with MS whose are currently in a stable state. |
Measure Participants | 25 | 25 |
Mean (Standard Deviation) [Total Score] |
5.4
(1.4)
|
3.8
(1.7)
|
Title | Incidence of Adverse Events |
---|---|
Description | The number of patients reporting adverse events over the course of the study |
Time Frame | Up to 3 months |
Outcome Measure Data
Analysis Population Description |
---|
[Not Specified] |
Arm/Group Title |
---|
Arm/Group Description |
Title | Change From Baseline in Concurrent Medications |
---|---|
Description | Initiation or discontinuation of any medications occurring over the course of the study; monitored by clinician and study personnel. |
Time Frame | Up to 3 months |
Outcome Measure Data
Analysis Population Description |
---|
[Not Specified] |
Arm/Group Title |
---|
Arm/Group Description |
Adverse Events
Time Frame | For individual subjects the time period was 3 months. From the initial enrollment to study closure, total monitoring time was 4 years. | |||
---|---|---|---|---|
Adverse Event Reporting Description | At each visit and in the weeks between visits, subjects were asked if they were experiencing any adverse events. | |||
Arm/Group Title | Cognitively Relapsing Patients | Stable Multiple Sclerosis Patients | ||
Arm/Group Description | For individuals experiencing cognitive relapses/exacerbations, 5ml/80 IU of Adrenocorticotropic Hormone will be administered through either subcutaneous or intramuscular self-injection (selected by the patient) for 5-days. Adrenocorticotropic Hormone: Acthar Gel will be administered in accordance with the recommendations set forth in the package insert. The dosage may be individualized according to the medical condition of each patient. Frequency and dose of the drug may be determined by considering the severity of the disease and the initial response of the patient. | Individuals whose Multiple Sclerosis is currently in a stable state (not currently or recently exacerbating) are age-matched with relapsing MS patients. There is no intervention for individuals with MS whose are currently in a stable state. | ||
All Cause Mortality |
||||
Cognitively Relapsing Patients | Stable Multiple Sclerosis Patients | |||
Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
Total | 0/25 (0%) | 0/25 (0%) | ||
Serious Adverse Events |
||||
Cognitively Relapsing Patients | Stable Multiple Sclerosis Patients | |||
Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
Total | 0/25 (0%) | 0/25 (0%) | ||
Other (Not Including Serious) Adverse Events |
||||
Cognitively Relapsing Patients | Stable Multiple Sclerosis Patients | |||
Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
Total | 0/25 (0%) | 0/25 (0%) |
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
Name/Title | Curtis Wojcik, Lab Coordinator |
---|---|
Organization | University at Buffalo |
Phone | 7163230551 |
cmwojcik@buffalo.edu |
- 465028